Literature DB >> 20194307

Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury.

Shusuke Yagi1, Masashi Akaike, Ken-ichi Aihara, Kazue Ishikawa, Takashi Iwase, Yasumasa Ikeda, Takeshi Soeki, Sumiko Yoshida, Yuka Sumitomo-Ueda, Toshio Matsumoto, Masataka Sata.   

Abstract

Activation of the renin-angiotensin system exacerbates atrial remodeling, leading to atrial fibrillation and thrombosis, especially in a condition with decreased NO bioavailability. Recently, it has been reported that statins reduce the incidence of atrial fibrillation through attenuation of atrial remodeling; however, the mechanisms have not been completely elucidated. Therefore, we aimed to clarify the beneficial effect of statin on atrial remodeling in condition with reduced NO bioavailability. Endothelial NO synthase(-/-) mice were sham operated or infused with angiotensin II (Ang II) via an osmotic minipump for 2 weeks, and Ang II-infused mice were divided into 3 treatment groups: pitavastatin, Tempol (a free radical scavenger), or vehicle. Echocardiography and electrocardiography showed that Ang II infusion caused left atrial enlargement and a high incidence of atrial fibrillation, whereas pitavastatin and Tempol prevented these abnormalities. In histological analysis, Ang II-induced atrial interstitial fibrosis, perivascular fibrosis, and cardiomyocyte hypertrophy were all attenuated by pitavastatin and Tempol. Immunohistochemical staining showed that Ang II downregulated thrombomodulin and tissue factor pathway inhibitor and upregulated tissue factor and plasminogen activator inhibitor 1 in the left atrium and that pitavastatin and Tempol corrected the thrombogenic condition. Moreover, pitavastatin and Tempol reduced Ang II-induced atrial superoxide production and atrial transforming growth factor-beta1 expression and Smad 2/3 phosphorylation. Atrial rac1-GTPase activity, known to activate NADPH oxidase, was attenuated by pitavastatin but not by Tempol. In conclusion, pitavastatin exerts endothelial NO synthase-independent protective actions against Ang II-induced atrial remodeling and atrial fibrillation with enhanced thrombogenicity through suppression of oxidant injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20194307     DOI: 10.1161/HYPERTENSIONAHA.109.146076

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  28 in total

Review 1.  Targeting NADPH oxidases in vascular pharmacology.

Authors:  Agata Schramm; Paweł Matusik; Grzegorz Osmenda; Tomasz J Guzik
Journal:  Vascul Pharmacol       Date:  2012-03-03       Impact factor: 5.773

Review 2.  Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.

Authors:  Christopher E Woods; Jeffrey Olgin
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

3.  Pitavastatin subacutely improves endothelial function and reduces inflammatory cytokines and chemokines in patients with hypercholesterolaemia.

Authors:  Bonpei Takase; Hidemi Hattori; Yoshihiro Tanaka; Masayoshi Nagata; Masayuki Ishihara
Journal:  Heart Asia       Date:  2013-09-13

4.  Angiotensin receptor blockers and statins could alleviate atrial fibrosis via regulating platelet-derived growth factor/Rac1/nuclear factor-kappa B Axis.

Authors:  Dongfang Yang; Jia Yuan; Gan Liu; Zhiyu Ling; Haiyan Zeng; Yunqing Chen; Yue Zhang; Qiang She; Xue Zhou
Journal:  Int J Med Sci       Date:  2013-04-26       Impact factor: 3.738

Review 5.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 6.  Targeting stem cell niches and trafficking for cardiovascular therapy.

Authors:  Nicolle Kränkel; Gaia Spinetti; Silvia Amadesi; Paolo Madeddu
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

7.  New take on the role of angiotensin II in cardiac hypertrophy and fibrosis.

Authors:  Mazen Kurdi; George W Booz
Journal:  Hypertension       Date:  2011-04-18       Impact factor: 10.190

8.  A new mechanism links preamyloid oligomer formation in the myocyte stress response associated with atrial fibrillation.

Authors:  Jason Pellman; Farah Sheikh
Journal:  J Mol Cell Cardiol       Date:  2014-12-23       Impact factor: 5.000

Review 9.  The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox.

Authors:  Demetrios Moris; Michael Spartalis; Eleftherios Spartalis; Georgia-Sofia Karachaliou; Georgios I Karaolanis; Gerasimos Tsourouflis; Diamantis I Tsilimigras; Eleni Tzatzaki; Stamatios Theocharis
Journal:  Ann Transl Med       Date:  2017-08

Review 10.  Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase.

Authors:  Ji-Youn Youn; Jun Zhang; Yixuan Zhang; Houzao Chen; Depei Liu; Peipei Ping; James N Weiss; Hua Cai
Journal:  J Mol Cell Cardiol       Date:  2013-05-02       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.